132 related articles for article (PubMed ID: 27169793)
1. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
[TBL] [Abstract][Full Text] [Related]
2. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Burton JH; Mazcko C; LeBlanc A; Covey JM; Ji J; Kinders RJ; Parchment RE; Khanna C; Paoloni M; Lana S; Weishaar K; London C; Kisseberth W; Krick E; Vail D; Childress M; Bryan JN; Barber L; Ehrhart EJ; Kent M; Fan T; Kow K; Northup N; Wilson-Robles H; Tomaszewski J; Holleran JL; Muzzio M; Eiseman J; Beumer JH; Doroshow JH; Pommier Y
Clin Cancer Res; 2018 Dec; 24(23):5830-5840. PubMed ID: 30061364
[TBL] [Abstract][Full Text] [Related]
3. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
Pommier Y; Cushman M
Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
[TBL] [Abstract][Full Text] [Related]
4. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Kummar S; Chen A; Ji J; Zhang Y; Reid JM; Ames M; Jia L; Weil M; Speranza G; Murgo AJ; Kinders R; Wang L; Parchment RE; Carter J; Stotler H; Rubinstein L; Hollingshead M; Melillo G; Pommier Y; Bonner W; Tomaszewski JE; Doroshow JH
Cancer Res; 2011 Sep; 71(17):5626-34. PubMed ID: 21795476
[TBL] [Abstract][Full Text] [Related]
6. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
[TBL] [Abstract][Full Text] [Related]
7. Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.
Kinders RJ; Hollingshead M; Lawrence S; Ji J; Tabb B; Bonner WM; Pommier Y; Rubinstein L; Evrard YA; Parchment RE; Tomaszewski J; Doroshow JH;
Clin Cancer Res; 2010 Nov; 16(22):5447-57. PubMed ID: 20924131
[TBL] [Abstract][Full Text] [Related]
8. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.
Tsakalozou E; Adane ED; Liang Y; Arnold SM; Leggas M
Cancer Chemother Pharmacol; 2014 Jul; 74(1):45-54. PubMed ID: 24807458
[TBL] [Abstract][Full Text] [Related]
9. Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs.
Muzzio M; Hu SC; Holleran JL; Parise RA; Eiseman JL; Yellow-Duke AE; Covey JM; Glaze ER; Engelke K; Egorin MJ; McCormick DL; Beumer JH
Cancer Chemother Pharmacol; 2015 May; 75(5):1015-23. PubMed ID: 25776905
[TBL] [Abstract][Full Text] [Related]
10. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
Mol Autism; 2018; 9():45. PubMed ID: 30140420
[TBL] [Abstract][Full Text] [Related]
11. Targeting Topoisomerase I in the Era of Precision Medicine.
Thomas A; Pommier Y
Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
Pfister TD; Hollingshead M; Kinders RJ; Zhang Y; Evrard YA; Ji J; Khin SA; Borgel S; Stotler H; Carter J; Divelbiss R; Kummar S; Pommier Y; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2012; 7(12):e50494. PubMed ID: 23284638
[TBL] [Abstract][Full Text] [Related]
13. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
[TBL] [Abstract][Full Text] [Related]
14. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
[TBL] [Abstract][Full Text] [Related]
15. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.
Devriese LA; Witteveen PE; Mergui-Roelvink M; Smith DA; Lewis LD; Mendelson DS; Bang YJ; Chung HC; Dar MM; Huitema AD; Beijnen JH; Voest EE; Schellens JH
Br J Clin Pharmacol; 2015 Aug; 80(2):253-66. PubMed ID: 25677219
[TBL] [Abstract][Full Text] [Related]
17. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
18. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis.
Huang X; Traganos F; Darzynkiewicz Z
Cell Cycle; 2003; 2(6):614-9. PubMed ID: 14504478
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776).
Beck DE; Agama K; Marchand C; Chergui A; Pommier Y; Cushman M
J Med Chem; 2014 Feb; 57(4):1495-512. PubMed ID: 24517248
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
